Vivos Therapeutics (VVOS) beat estimates for the third quarter, but the quarter's most important figure is the $247,000 in cash on hand at September 30. The company lost $0.07 per share, well ahead of the -$0.30 consensus, a 76.7% surprise and an 85.7% year-over-year improvement in earnings. Revenue of $6.41 million topped the $5.48 million consensus by 17.0% and rose 24% from the second quarter's $5.2 million, yet it still fell 5.4% from a year ago. The beat is real on paper. The setup it lands in is far more fragile than the surprise suggests.
The quality of the beat deserves scrutiny. Net loss narrowed to $2.0 million from $5.4 million, but that included about $2.9 million of other income from reversing a previously recorded Employee Retention Credit liability. The operating loss was $3.9 million. That is an 18% improvement from $4.7 million, driven by a 17% cut in operating expenses as general and administrative costs fell $1.4 million. Even so, operations are not close to breakeven. The per-share comparison is also flattered by heavy dilution: weighted shares rose to 26.5 million from 11.0 million a year earlier, and 33.8 million shares were outstanding at quarter-end. Gross margin fell to 52% from 58% a year ago, continuing a slide from 60% in the first quarter and 57% in the second. Product revenue dropped to $1.8 million as Vivos pivots away from appliance sales to dentists. Service revenue, the strategic replacement, grew just 1% year over year to $4.6 million in the quarter, although it is up 57% for the nine months on the Nevada sleep-testing build-out.
The conference-call record adds an unusual complication. The material provided as the third-quarter call is effectively a near-verbatim replay of the second-quarter call. It contains the same figures, script and Q&A, and it discloses no third-quarter results. Investors therefore have no fresh management commentary on the quarter just reported. The trajectory visible across the earlier calls was not encouraging:
- Revenue went nearly flat in the second quarter after a strong first quarter.
- Management promised the second quarter would show emerging profits, but it posted a $5.5 million net loss.
- The cash-flow-positive target slipped from 'by end of 2026' to 'near end of 2026 or early 2027.'
- First-half operating cash burn rose to $9.2 million from $7.3 million.
- The CFO is departing.
The third-quarter revenue rebound is a welcome break in that pattern, but the gross-margin decline continued.
Management's growth story rests on a pipeline of initiatives that remain largely unproven:
- CPAP remote patient monitoring, with 5,000-7,500 enrollable patients at an estimated $40-50 per patient per night
- A DME-based CPAP program targeted for an early fourth-quarter launch at $150,000-$250,000 a month in contribution at scale
- EEG insomnia testing reimbursed at roughly $800 per test
- Arizona and Florida cardiology affiliations expected to produce revenue in the first half of 2027
- Renegotiated payer contracts
The release says these should contribute beginning in the fourth quarter and increasingly through 2027. The near-term risk, however, is existential rather than operational. Vivos carries going-concern doubt and faces a December 2, 2026 deadline to regain compliance with Nasdaq's minimum bid price, contingent on stockholder approval of a reverse split. If the stock closes at $0.10 or less for ten consecutive business days, Nasdaq would issue an immediate delisting determination. The company did regain compliance with the stockholders' equity requirement after closing the SOD Sciences transaction in October and exchanging about $6.1 million of debt for equity. Total liabilities fell to $20.7 million from $26.7 million. Still, roughly $5 million in annualized cost savings cannot fund a business with a quarter-end cash balance this thin, and further dilution, including from outstanding preferred stock, appears likely.
The market has priced in that distress. Shares traded at $0.10 heading into the report, down 68.1% from the $0.31 open after the August report. They sit 85% below the 200-day moving average and just 14.5% above the 52-week low of $0.09 set on November 11. The stock has given back the entire move to its inter-earnings high of $0.46 on August 31. Investor sentiment turned sharply more negative, falling from -0.23 to -0.55, a meaningful deterioration that reflects investors' focus on solvency over revenue growth. The AVWAP trend reading remains negative.
The bottom line is that Vivos delivered a headline beat on both lines, but much of the bottom-line improvement came from a one-time liability reversal, margins kept eroding, and per-share gains were diluted. The quarter offered few answers to the questions that matter most. Whether the CPAP, EEG and cardiology initiatives can ramp quickly enough is secondary to whether the company can secure funding and preserve its Nasdaq listing in the coming weeks.